Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer

Cancer Research

Volumn 65, Issue 1, 2005, Pages 338-348

  Lo, Hui Wen ^a   Xia, Weiya ^a   Wei, Yongkun ^a   Ali Seyed, Mohamed ^a   Huang, Shiu Feng ^b   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CELL NUCLEUS; COHORT ANALYSIS; DIAGNOSTIC VALUE; FEMALE; GENE; IMMUNOHISTOCHEMISTRY; LIVER REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR LOCALIZATION;

BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN D1; FEMALE; HUMANS; KI-67 ANTIGEN; MOUTH NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 11244280137     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Marti U, Hug M. Acinar and cellular distribution and mRNA expression of the epidermal growth factor receptor are changed during liver regeneration. J Hepatol 1995;23:318-27.
2. Marti U, Burwen SJ, Wells A, et al. Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 1991;13:15-20.
3. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001;3:802-8.
4. Kamio T, Shigematsu K, Sou H, Kawai K, Tsuchiyama H. Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 1990;21:277-82.
5. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994;69:1120-5.
6. Marti U, Ruchti C, Kampf J, et al. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid 2001;11:137-45.
7. Tervahauta A, Syrjanen S, Syrjanen K. Epidermal growth factor receptor, c-erbB-2 proto-oncogene and estrogen receptor expression in human papillomavirus lesions of the uterine cervix. Int J Gynecol Pathol 1994;13:234-40.
8. Schausberger E, Eferl R, Parzefall W, et al. Induction of DNA synthesis in primary mouse hepatocytes is associated with nuclear pro-transforming growth factor α and erbb-1 and is independent of c-jun. Carcinogenesis 2003;24:835-41.
9. Raabe TD, Deadwyler G, Varga JW, Devries GH. Localization of neuregulin isoforms and erbB receptors in myelinating glial cells. Glia 2004;45:197-207.
10. Xie Y, Hung MC. Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. Biochem Biophys Res Commun 1994;203:1589-98.
11. Offterdinger M, Schofer C, Weipoltshammer K, Grunt TW. c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol 2002;157:929-39.
12. Ni CY, Murphy MP, Golde TE, Carpenter G. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001;294:2179-81.
13. Rakowicz-Szulczynska EM, Herlyn M, Koprowski H. Nerve growth factor receptors in chromatin of melanoma cells, proliferating melanocytes, and colorectal carcinoma cells in vitro. Cancer Res 1988;48:7200-6.
14. Zhang FX, Lai CH, Lai SK, Yung KK, Shum DK, Chan YS. Neurotrophin receptor immunostaining in the vestibular nuclei of rats. Neuroreport 2003;14:851-5.
15. Zwaagstra JC, Guimond A, O'Connor-McCourt MD. Predominant intracellular localization of the type I transforming growth factor-β receptor and increased nuclear accumulation after growth arrest. Exp Cell Res 2000;258:121-34.
16. Maher PA. Nuclear Translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J Cell Biol 1996;134:529-36.
17. Reilly JF, Maher PA. Importin β-mediated nuclear import of fibroblast growth factor receptor: role in cell proliferation. J Cell Biol 2001;152:1307-12.
18. Wang SC, Lien HC, Xia W, et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 2004;6:251-61.
19. Jans DA, Hassan G. Nuclear targeting by growth factors, cytokines, and their receptors: a role in signaling? Bioessays 1998;20:400-11.
20. Bader T, Weitzerbin J. Nuclear accumulation of interferon γ. Proc Natl Acad Sci U S A 1994;91:11831-5.
21. Larkin J III, Johnson HM, Subramaniam PS. Differential nuclear localization of the IFNGR-1 and IFNGR-2 subunits of the IFN-γ receptor complex following activation by IFN-γ. J Interferon Cytokine Res 2000;20:565-76.
22. Subramaniam PS, Green MM, Larkin J III, Torres BA, Johnson HM. Nuclear translocation of IFN-γ is an intrinsic requirement for its biologic activity and can be driven by a heterologous nuclear localization sequence. J Interferon Cytokine Res 2001;21:951-9.
23. Subramaniam PS, Johnson HM. Lipid microdomains are required sites for the selective endocytosis and nuclear translocation of IFN-γ, its receptor chain IFN-γ receptor-I, and the phosphorylation and nuclear translocation of STAT1α. J Immunol 2002;169:1959-69.
24. Jans DA, Briggs LJ, Gustin SE, Jans P, Ford S, Young IG. The cytokine interleukin-5 (IL-5) effects cotransport of its receptor subunits to the nucleus in vitro. FEBS Lett 1997;410:368-72.
25. Curtis BM, Widmer MB, deRoos P, Qwarnstrom EE. IL-1 and its receptor are translocated to the nucleus. J Immunol 1990;144:1295-303.
26. Grasl-Kraupp B, Schausberger E, Hufnagl K, et al. A novel mechanism for mitogenic signaling via protransforming growth factor α within hepatocyte nuclei. Hepatology 2002;35:1372-80.
27. Wang S-C, Lien H-C, Xia W, et al. Binding at and transactivation of COX-2 promoter by nuclear tyrosine kinase receptor ErbB2. Cancer Cell. In press 2004.
28. Carpenter G. Nuclear localization and possible functions of receptor tyrosine kinases. Curr Opin Cell Biol 2003;15:143-8.
29. Wells A, Marti U. Signalling shortcuts: cell-surface receptors in the nucleus? Nat Rev Mol Cell Biol 2002;3:697-702.
30. Cohen S. Ushiro H, Stoscheck C, Chinkers M. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 1982;257:1523-31.
31. Hu P, Margolis B, Skolnik EY, Lammers B, Ullrich A, Schlessinger J. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol Cell Biol 1992;12:981-90.
32. Anderson D, Koch CA, Grey L, Ellis C, Moran MF, Pawson T. Binding of SH2 domains of phospholipase Cγ1, GAP, and Src to activated growth factor receptors. Science 1990;250:979-82.
33. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21.
34. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
35. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37 Suppl 4:S9-15.
36. Xia W, Lau YK, Zhang HZ, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999;5:4164-74.
37. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 1994;29:41-9.
38. Gohring UJ, Ahr A, Scharl A, et al. Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma. J Soc Gynecol Investig 1995;2:653-9.
39. Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003;97:1841-8.
40. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003;106:758-65.
41. Seshadri R, McLeay WR, Horsfall DJ, McCaul K. Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer. Int J Cancer 1996;69:23-7.
42. Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992;13:3-17.
43. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-807.
44. Kanematsu T, Yano S, Uehara H, Bando Y, Sone S. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 2003;13:289-98.
45. Paez JG, Janne PA, Lee JC, et al. EGFR Mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:497-500.
46. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
47. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 2004;305:1163-7.
48. Winters ZE, Hunt NC, Bradburn MJ, et al. Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer. Association with prognosis. Eur J Cancer 2001;37:2405-12.
49. Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 2004;10:3815-24.
50. KIP1 phosphorylation by PKB/Akt leads to poor breast cancer prognosis. Breast Cancer Res 2003;5:162-3.
51. Hu MC, Lee DF, Xia W, et al. IκB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004;117:225-37.
52. Karin M, Cao Y, Greten FR, Li ZW, NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
53. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-89.
54. Wells J, Graveel CR, Bartley SM, Madore SJ, Farnham PJ. The identification of E2F1-specific target genes. Proc Natl Acad Sci U S A 2002;99:3890-5.
55. Lin SY, Xia W, Wang JC, et al. β-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 2000;97:4262-6.
56. Hsu SM, Raine L, Fanger H. Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
57. Camp RL, Rimm EB, Rimm DL. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999;86:2259-65.
58. Villena-Heinsen C, Meyberg R, Axt-Fliedner R, Reitnauer K, Reichrath J, Friedrich M. Immunohistochemical analysis of 1,25-dihydroxyvitamin-D3-receptors, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma. Anticancer Res 2002;22:2261-7.
59. Bourguignon L, Lan K-h, Singleton P, Lin S-Y, Yu D, Hung M-C. Localizing the EGF receptor [reply]. Nat Cell Biol 2002;4:E22-3.
60. Marti U, Wells A. The nuclear accumulation of a variant epidermal growth factor receptor (EGFR) lacking the transmembrane domain requires coexpression of a full-length EGFR. Mol Cell Biol Res Commun 2000;3:8-14.
61. Stachowiak EK, Maher PA, Tucholski J, et al. Nuclear accumulation of fibroblast growth factor receptors in human glial cells-association with cell proliferation. Oncogene 1997;14:2201-11.
62. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-7.
63. Ferrero JM, Ramaioli A, Largillier R, et al. Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol 2001;12:841-6.
64. Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001;3:245-52.
65. Asada M, Yamada T, Ichijo H, et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J 1999;18:1223-34.
66. El-Deiry WS. Akt takes centre stage in cell-cycle deregulation. Nat Cell Biol 2001;3:E71-3.
67. Huang S, Shu L, Dilling MB, et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell 2003;11:1491-501.
68. 1 arrest. Nat Med 2002;8:1153-60.
69. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002;8:1145-52.
70. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136-44.
71. Burgering BM, Kops GJ. Cell cycle and death control: long live forkheads. Trends Biochem Sci 2002;27:352-60.
72. Tran H, Brunet A, Griffith EC, Greenberg ME. The many forks in FOXO's road. Sci STKE 2003;2003:RE5.
73. Tschugguel W, Schneeberger C, Unfried G, et al. Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade. Breast Cancer Res Treat 1999;56:145-51.